

New England Biolabs Certificate of Analysis

Product Name: *BanI*
Catalog #: *R0118S/L*
Concentration: *20,000 units/ml*
Unit Definition: *One unit is defined as the amount of enzyme required to digest 1 µg of Lambda DNA in 1 hour at 37°C in a total reaction volume of 50 µl.*
Lot #: *0271412*
Assay Date: *12/2014*
Expiration Date: *12/2016*
Storage Temp: *-20 °C*
Storage Conditions: *50 mM KCl, 10 mM Tris-HCl (pH 7.4), 1 mM DTT, 0.1 mM EDTA, 50% Glycerol, 200 µg/ml BSA*
Specification Version: *PS-R0118S/L v1.0*
Effective Date: *17 Oct 2013*

Assay Name/Specification (minimum release criteria)	Lot #0271412
Exonuclease Activity (Radioactivity Release) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of a mixture of single and double-stranded [³ H] <i>E. coli</i> DNA and a minimum of 100 units of BanI incubated for 4 hours at 37°C releases <0.1% of the total radioactivity.	Pass
Ligation and Recutting (Terminal Integrity) - After a 10-fold over-digestion of Lambda DNA with BanI, >95% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with BanI.	Pass
Non-Specific DNase Activity (16 hour) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of Lambda DNA and a minimum of 20 Units of BanI incubated for 16 hours at 37°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis. NOTE: although no nuclease degradation is detected under these conditions, extended incubations and/or high concentrations of this enzyme may result in star activity. See the product FAQ for recommended reaction conditions for this enzyme.	Pass
Protein Purity Assay (SDS-PAGE) - BanI is >95% pure as determined by SDS PAGE analysis using Coomassie Blue detection.	Pass

* The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.

M. W. Southworth

Kerri Sakowski

Authorized by
Maurice Southworth
17 Oct 2013

Inspected by
Kerri Sakowski
31 Dec 2014

